开拓药业-B涨超5% 拟折让15.03%发行认购股份筹资 用于KX-826 III期临床试验

Core Viewpoint - 开拓药业-B's stock price increased by over 5%, reaching 2.15 HKD, with a trading volume of 5.5445 million HKD, following the announcement of a share subscription deal [1] Group 1: Share Subscription Announcement - 开拓药业-B plans to issue 30.4875 million subscription shares to 华圆管理咨询(香港)有限公司, a wholly-owned subsidiary of 中新苏州工业园区创业投资有限公司, at a subscription price of 1.64 HKD per share [1] - The subscription price represents a discount of approximately 15.03% compared to the last closing price of 1.93 HKD [1] - The net proceeds from the subscription are expected to be around 49.78 million HKD, which will be used for general working capital and the Phase III clinical trial of KX-826 [1]